On April 1, 2020, the U.S. Food and Drug Administration (FDA) ordered all ranitidine drug manufacturers that are sold under the Zantac name to recall the products from the shelves. This was due to the presence of an impurity known as N-nitrosodimethylamine (NDMA), a substance that has been linked to cancer. This contaminant can build up in the medicine with prolonged storage and potentially harm those who have consumed it.
Pharmaceutical companies play an active role in our society in researching, discovering and developing new drugs that can help diseases and conditions. However, some reports show that the manufacturers of Zantac and ranitidine heartburn medication were aware of possible NDMA contamination since the 1
Thousands of claimants who have developed cancer as a result of Zantac consumption can claim compensation for the damage they have suffered as the manufacturers are not responsible and continue to sell such a dangerous product. However, we must note that the “no warning complaints” of a state can differ from those of a state. In some states, branded drug manufacturers are required to warn generic users of the potential risks of the drugs they sell, and in some states this type of obligation is not required.
(Click this article to learn more.)